---
title: "Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death "
description: "Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and decreased the risk of recurrence and metastasis events by 60%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261731590.md"
published_at: "2025-10-18T14:38:10.000Z"
---

# Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death 

> Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and decreased the risk of recurrence and metastasis events by 60%

Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and the risk of recurrence and metastasis events by 60%

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing | 04:30 PM EST, 02/06/2026 (MT Newswires) -- Johannes Jacobus Oosthuizen, President, US Market, on February 06, 2026, sold | [Link](https://longbridge.com/en/news/275175518.md) |
| Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | [Link](https://longbridge.com/en/news/274841608.md) |
| MSD receives FDA approval for Keytruda combo to treat ovarian cancer | MSD has received FDA approval for Keytruda and Keytruda Qlex, in combination with paclitaxel, for treating platinum-resi | [Link](https://longbridge.com/en/news/275742611.md) |
| FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer | The FDA has approved Merck's KEYTRUDA regimen for treating adults with PD-L1 positive platinum-resistant ovarian cancer. | [Link](https://longbridge.com/en/news/275598070.md) |
| Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX | Merck announced that the U.S. FDA has approved KEYTRUDA (pembrolizumab and berahyaluronidase alfa-pmph) for treating adu | [Link](https://longbridge.com/en/news/275617117.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
